🔴 Definium Therapeutics is trading 4.2% down today — no fresh company-specific negative catalyst identified

Definium Therapeutics is trading 4.2% down at $42.05, with no fresh company-specific negative catalyst identified on August 14, 2026.

• The latest major announcement was August 12 positive Phase 3 Voyage data for DT120 ODT.
• The data included a statistically significant 5.4-point placebo-adjusted HAM-A improvement.
• Broader markets are modestly lower, but the decline does not meet the supplied threshold for a clear macro-driven explanation.